Greenwich LifeSciences (GLSI) shares jump 42% after FDA approves commercial GP2 for Phase III breast cancer prevention trial, reducing regulatory risks ahead of license application.
Greenwich LifeSciences (GLSI) announces 6-year share lock-up extension for directors and officers to support FLAMINGO-01 breast cancer trial through September 2026.
Greenwich LifeSciences reports 80% reduction in breast cancer recurrence rates in FLAMINGO-01 trial using GLSI-100 immunotherapy treatment.
FDA Fast-Tracks GLSI-100, an immunotherapy for HER2+ breast cancer. It aims to prevent recurrence in HLA-A*02 patients. Early data showed >80% reduction in recurrence & good safety. Now in Phase III, it could save lives by preventing metastatic spread.
